EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness of the Local Additional Risk Minimisation Measures for Yellow Fever Vaccine in the United Kingdom: A Survey of Healthcare Professionals and Vaccinees

Leila Karimi, Artis Luguzis, Neha Pawar, Marine Dufournet, Fernando Morelli, Yael Thollot, Marie-Caroline Guichard, Guillemette Petti, Lin Li iD

Pharmacoepidemiology and Drug Safety · 2026

DOI: 10.1002/pds.70359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Leila Karimi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Real World Solutions, IQVIA, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Yellow Fever Vaccine, Health Personnel, Yellow Fever, Risk Management. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Following two fatal adverse reactions after yellow fever (YF) vaccination in the United Kingdom (UK) between 2018 and 2019, both involving unapproved use, the UK Medicines and Healthcare products Regulatory Agency (MHRA) mandated that the Marketing Authorisation Holder incorporate a checklist into the YF vaccine (STAMARIL) Risk Management Plan. This checklist was implemented as part of the local additional risk minimisation measures (aRMMs) in 2021, along with an updated patient information leaflet (PIL), to assist UK healthcare professionals (HCPs) in conducting risk‐benefit evaluations during YF vaccination consultations. We evaluated the effectiveness of these interventions among HCPs at authorised YF vaccination centres and vaccinees across the UK.

Methods

Using a cross‐sectional online survey among eligible UK HCPs and YF vaccinees in 2023, we assessed five effectiveness indicators: four for HCPs (aRMMs YF pre‐vaccination checklist awareness, standardised YF pre‐vaccination checklist utilisation, PIL distribution and knowledge and understanding of checklist's key safety messages) and one for vaccinees (PIL receipt). Each indicator was successful if achieved by ≥ 80% of the respondents. The proportion of desirable answers provided for each indicator with 95% confidence interval (CI) was calculated.

Results

Among the 153 HCPs who responded, 73.9% (95% CI: 66.4%–80.2%) were aware of the aRMMs checklist, 89.5% (95% CI: 83.7%–93.5%) utilised any standardised checklist(s), 92.2% (95% CI: 86.8%–95.5%) distributed the PIL to vaccinees and 46.4% (95% CI: 38.7%–54.3%) provided desirable answers to ≥ 80% of the questions on knowledge and understanding of key safety messages. Among 125 vaccinees who responded, 87.2% (95% CI: 80.2%–92.0%) confirmed PIL receipt.

Conclusion

Three of the five effectiveness indicators were successful. Importantly, no YF vaccination errors were reported in the UK National Travel Health Network and Centre Annual Return reports (2021–2024) following aRMM implementation. Therefore, these findings suggest that the local aRMMs provide an effective framework for the safe administration of YF vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Yellow Fever VaccineHealth PersonnelYellow FeverRisk ManagementHumansUnited KingdomCross-Sectional StudiesSurveys and QuestionnairesFemaleRisk AssessmentChecklistVaccinationMaleAdultMiddle Aged

Stichwörter der Autor:innen

additional risk minimisation measures (aRMMs)cross‐sectional surveyeffectiveness evaluationpatient information leafletpre‐vaccination checklistyellow fever vaccine

Substanzen

Yellow Fever Vaccine

Autor:innen und Institutionen

  • Real World Solutions, IQVIA, Amsterdam, the Netherlands.
  • Real World Solutions, IQVIA, Riga, Latvia.
  • Real World Solutions, IQVIA, Gurugram, India.
  • Global Biostatistical Sciences, Sanofi, Marcy l'Etoile, France.
  • Global Medical, Sanofi, Lyon, France.
  • Medical Operations and Effectiveness, Sanofi, Lyon, France.

ORCID-Profile: Lin Li

Förderung

  • Sanofi

Zitieren

APA

Karimi, L., Luguzis, A., Pawar, N., Dufournet, M., Morelli, F., Thollot, Y., Guichard, M. C., Petti, G., & Li, L. (2026). Effectiveness of the Local Additional Risk Minimisation Measures for Yellow Fever Vaccine in the United Kingdom: A Survey of Healthcare Professionals and Vaccinees. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70359

Vancouver

Karimi L, Luguzis A, Pawar N, Dufournet M, Morelli F, Thollot Y, et al. Effectiveness of the Local Additional Risk Minimisation Measures for Yellow Fever Vaccine in the United Kingdom: A Survey of Healthcare Professionals and Vaccinees. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70359

BibTeX
@article{Karimi2026,
  author = {Karimi, Leila and Luguzis, Artis and Pawar, Neha and Dufournet, Marine and Morelli, Fernando and Thollot, Yael and Guichard, Marie-Caroline and Petti, Guillemette and Li, Lin},
  title = {Effectiveness of the Local Additional Risk Minimisation Measures for Yellow Fever Vaccine in the United Kingdom: A Survey of Healthcare Professionals and Vaccinees},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  doi = {10.1002/pds.70359}
}
Kostenlos starten →